The peptide and protein therapeutics are an important class of medicines, which are administered through the oral route to treat different diseases, which include gastric, hormonal, and metabolic disorders. These drugs hold significant potential to improve the human health. The global oral proteins and peptides market was valued at $643 million in 2016, and is estimated to reach at $8,233 million by 2028, registering a CAGR of 11.7% from 2022 to 2028. Research Beam Model: Research Beam Product ID: 2988953 5370 USD New
Oral Proteins and Peptides Market by Drug Type (Linaclotide, Plecanatide, Calcitonin, Insulin, and Octreotide) and Application (Gastric & Digestive Disorders, Bone Diseases, Diabetes, and Hormonal Disorders) - Global Opportunity Analysis and Industry Forecast, 2017-2028
 
 

Oral Proteins and Peptides Market by Drug Type (Linaclotide, Plecanatide, Calcitonin, Insulin, and Octreotide) and Application (Gastric & Digestive Disorders, Bone Diseases, Diabetes, and Hormonal Disorders) - Global Opportunity Analysis and Industry Forecast, 2017-2028

  • Category : Pharmaceuticals
  • Published On : March   2018
  • Pages : 120
  • Publisher : Allied Market Research
 
 
 

The peptide and protein therapeutics are an important class of medicines, which are administered through the oral route to treat different diseases, which include gastric, hormonal, and metabolic disorders. These drugs hold significant potential to improve the human health. The global oral proteins and peptides market was valued at $643 million in 2016, and is estimated to reach at $8,233 million by 2028, registering a CAGR of 11.7% from 2022 to 2028.

Upsurge in collaboration between pharmaceutical companies for drug development and surge in prevalence of chronic diseases are the key factors that augment the growth of the global oral proteins and peptides market. Moreover, rise in geriatric population and improvement in healthcare infrastructure are expected to boost the market growth.

However, low bioavailability of oral proteins and peptides and high cost associated with drug development are some of the factors that restrain the market growth. Conversely, increase in purchasing power of developing countries and rise in R&D activities by pharmaceutical companies are expected to provide new opportunities for market players in the near future.

The oral proteins and peptides market is segmented into drug type, application, and region. By drug type, the market is divided into linaclotide, plecanatide, calcitonin, insulin, and octreotide. By application, it is categorized into gastric & digestive disorders, bone diseases, diabetes, and hormonal disorders. Based on region, it is analyzed across the U.S. and rest of the world.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis of the current market trends and future estimations from 2016 to 2028 to identify the prevailing opportunities.
  • The oral proteins and peptides market size and estimations are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on region assists to understand the regional market and the strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Drug Type

  • Linaclotide
  • Plecanatide
  • Calcitonin
  • Insulin
  • Octreotide

By Application

  • Gastric & Digestive Disorders
  • Bone Diseases
  • Diabetes
  • Hormonal Disorders

By Region

  • U.S.
  • Rest of the world

The list of key players operating in this market includes:

  • Allergan plc
  • AstraZeneca plc
  • Biocon Limited
  • Chiasma, Inc.
  • Proxima Concepts Limited (Diabetology Ltd.)
  • Generex Biotechnology Corp.
  • Novo Nordisk A/S
  • Synergy Pharmaceuticals Inc.
  • Tarsa Therapeutics Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Clinical trials
3.4. Top player positioning, 2018
3.5. Patent analysis, 2010-2017

3.5.1. Patent analysis, by year (2010-2017)
3.5.2. Patent analysis, by country

3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in collaboration between pharmaceutical companies for drug development
3.6.1.2. Surge in prevalence of chronic diseases
3.6.1.3. Rise in geriatric population and improvement in healthcare infrastructure

3.6.2. Restraints

3.6.2.1. Low bioavailability of oral proteins and peptides
3.6.2.2. High costs associated with drug development

3.6.3. Opportunities

3.6.3.1. Increase in purchasing power of emerging economics
3.6.3.2. Increase in R&D activities by pharmaceutical companies

CHAPTER 4: ORAL PROTEINS AND PEPTIDES MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Linaclotide

4.2.1. Key market trends
4.2.2. Market size and forecast

4.3. Plecanatide

4.3.1. Key market trends
4.3.2. Market size and forecast

4.4. Calcitonin

4.4.1. Key market trends
4.4.2. Market size and forecast

4.5. Insulin

4.5.1. Key market trends
4.5.2. Market size and forecast

4.6. Octreotide

4.6.1. Key market trends
4.6.2. Market size and forecast

CHAPTER 5: ORAL PROTEINS AND PEPTIDES MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Gastric & digestive disorders

5.2.1. Market size and forecast

5.3. Bone diseases

5.3.1. Market size and forecast

5.4. Diabetes

5.4.1. Market size and forecast

5.5. Hormonal disorders

5.5.1. Market size and forecast

CHAPTER 6: ORAL PROTEINS AND PEPTIDES MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. U.S.

6.2.1. Key market trends
6.2.2. Market size and forecast

6.3. Rest of the world

6.3.1. Key market trends
6.3.2. Market size and forecast

CHAPTER 7: COMPANY PROFILES

7.1. Allergan Plc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. AstraZeneca PLC

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. Biocon Limited

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. Chiasma Inc.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Product portfolio
7.4.4. Key strategic moves and developments

7.5. Generex Biotechnology Corp.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Key strategic moves and developments

7.6. Novo Nordisk A/S

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. Oramed Pharmaceuticals Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Product portfolio
7.7.4. Key strategic moves and developments

7.8. Proxima Concepts Limited (Diabetology Ltd.)

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio

7.9. Synergy Pharmaceuticals Inc.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Key strategic moves and developments

7.10. Tarsa Therapeutics Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Product portfolio
7.10.4. Key strategic moves and developments

LIST OF TABLES

TABLE 01. COMPLETED CLINICAL TRIALS IN ORAL PROTEIN AND PEPTIDES MARKET
TABLE 02. GLOBAL ORAL PROTEINS AND PEPTIDES MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 03. GLOBAL ORAL PROTEINS AND PEPTIDES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 04. ORAL PROTEINS AND PEPTIDES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. ALLERGAN: COMPANY SNAPSHOT
TABLE 06. ALLERGAN: OPERATING SEGMENTS
TABLE 07. ALLERGAN: PRODUCT PORTFOLIO
TABLE 08. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 09. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 10. BIOCON: COMPANY SNAPSHOT
TABLE 11. BIOCON: OPERATING SEGMENTS
TABLE 12. BIOCON: PRODUCT PORTFOLIO
TABLE 13. CHIASMA: COMPANY SNAPSHOT
TABLE 14. CHIASMA: PRODUCT PORTFOLIO
TABLE 15. GENEREX: COMPANY SNAPSHOT
TABLE 16. GENEREX: OPERATING SEGMENTS
TABLE 17. GENEREX: PRODUCT PORTFOLIO
TABLE 18. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 19. NOVO NORDISK: OPERATING SEGMENTS
TABLE 20. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 21. ORAMED: COMPANY SNAPSHOT
TABLE 22. ORAMED: PRODUCT PORTFOLIO
TABLE 23. PROXIMA CONCEPTS: COMPANY SNAPSHOT
TABLE 24. PROXIMA CONCEPTS: OPERATING SEGMENTS
TABLE 25. PROXIMA CONCEPTS: PRODUCT PORTFOLIO
TABLE 26. SYNERGY: COMPANY SNAPSHOT
TABLE 27. SYNERGY: PRODUCT PORTFOLIO
TABLE 28. TARSA: COMPANY SNAPSHOT
TABLE 29. TARSA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. ORAL PROTEINS AND PEPTIDES MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS, 2028
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 06. TOP PLAYER POSITIONING, 2018
FIGURE 07. PATENT REGISTERED/APPROVED, BY YEAR
FIGURE 08. PATENT REGISTERED, BY COUNTRY
FIGURE 09. ORAL PROTEINS AND PEPTIDES MARKET: IMPACT ANALYSES
FIGURE 10. DIABETES BURDEN: KEY TAKEAWAYS, 2014
FIGURE 11. GLOBAL ELDERLY POPULATION (AGED 65 AND ABOVE), BY REGION (2015, 2030, AND 2050)
FIGURE 12. ORAL PROTEINS AND PEPTIDES MARKET SEGMENTATION, BY DRUG TYPE
FIGURE 13. ORAL PROTEINS AND PEPTIDES MARKET FOR LINACLOTIDE, 2016-2028 ($MILLION)
FIGURE 14. ORAL PROTEINS AND PEPTIDES MARKET FOR PLECANATIDE, 2017-2028 ($MILLION)
FIGURE 15. ORAL PROTEINS AND PEPTIDES MARKET FOR CALCITONIN, 2020-2028 ($MILLION)
FIGURE 16. ORAL PROTEINS AND PEPTIDES MARKET FOR INSULIN, 2020-2028 ($MILLION)
FIGURE 17. ORAL PROTEINS AND PEPTIDES MARKET FOR OCTREOTIDE, 2022-2028 ($MILLION)
FIGURE 18. ORAL PROTEINS AND PEPTIDES MARKET SEGMENTATION, BY APPLICATION
FIGURE 19. ORAL PROTEINS AND PEPTIDES MARKET FOR GASTRIC & DIGESTIVE DISORDERS, 2016-2028 ($MILLION)
FIGURE 20. ORAL PROTEINS AND PEPTIDES MARKET FOR BONE DISEASES, 2017-2028 ($MILLION)
FIGURE 21. ORAL PROTEINS AND PEPTIDES MARKET FOR DIABETES, 2020-2028 ($MILLION)
FIGURE 22. ORAL PROTEINS AND PEPTIDES MARKET FOR HORMONAL DISORDERS, 2022-2028 ($MILLION)
FIGURE 23. ORAL PROTEINS AND PEPTIDES MARKET SEGMENTATION, BY REGION
FIGURE 24. U.S. ORAL PROTEINS AND PEPTIDES MARKET, 2016-2028 ($MILLION)
FIGURE 25. REST OF THE WORLD ORAL PROTEINS AND PEPTIDES MARKET, 2017-2028 ($MILLION)
FIGURE 26. ALLERGAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 27. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. ASTRAZENECA: NET SALES, 2015-2017 ($MILLION)
FIGURE 29. ASTRAZENECA: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 30. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. BIOCON: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. BIOCON: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. BIOCON: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34. NOVO NORDISK: NET SALES, 2015-2017 ($MILLION)
FIGURE 35. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 36. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

PURCHASE OPTIONS
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT